3nAG

3nAG is a novel semi-synthetic C-12 dithiocarbamate andrographolide analogue developed as an anticancer agent. Synthesized from natural andrographolide isolated from *Andrographis paniculata*, 3nAG features substituted dithiocarbamate moieties at the C12 position, which significantly enhances its lipophilicity, cytotoxic activity, and selectivity against breast cancer cells (such as the MCF-7 cell line). Due to its high hydrophobicity, 3nAG has been formulated as a nanosuspension stabilized with chitosan derivatives (such as naphthyl-grafted succinyl chitosan, or NSC) to improve its water solubility and pharmacological efficacy. Preclinical studies have investigated 3nAG in combination with Mcl-1-targeting siRNA (siMcl-1) to overcome compensatory Mcl-1 upregulation and synergistically induce apoptosis in breast cancer cells.

Other names

12-dithiocarbamate-14-deoxyandrographolide analogueC-12 dithiocarbamate andrographolide analogueC12 dithiocarbamate andrographolide analogueC 12 dithiocarbamate andrographolide analogueandrographolide analogue 3nAG